LOX and neoplasm: These data are in line with decreases in stromal fibrillar collagen content (Fig. 4d) confirming that inhibition of lysyl oxidase family activity in combination with chemotherapy leads to a reduction in stromal collagen content, decreases in tumor stiffness and improved perfusion, which likely contribute to the potentiation of gemcitabine efficacy in the KPC mouse model of PDAC.